Long-term follow-up of tislelizumab combined with anlotinib in a single patient with metastatic type B3 thymoma: a case report.

Jiang T, Gao C, Ding F, Chen S, Chen Q.

Open source

DOI: 10.3389/fonc.2026.1856689
Published: 2026-08-19
Container: Front Oncol
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fonc.2026.1856689,
  title = {Long-term follow-up of tislelizumab combined with anlotinib in a single patient with metastatic type B3 thymoma: a case report.},
  author = {Jiang T and  Gao C and  Ding F and  Chen S and  Chen Q.},
  year = {2026},
  journal = {Front Oncol},
  doi = {10.3389/fonc.2026.1856689},
  url = {https://doi.org/10.3389/fonc.2026.1856689}
}

RIS

TY  - JOUR
TI  - Long-term follow-up of tislelizumab combined with anlotinib in a single patient with metastatic type B3 thymoma: a case report.
AU  - Jiang T
AU  -  Gao C
AU  -  Ding F
AU  -  Chen S
AU  -  Chen Q.
PY  - 2026
JO  - Front Oncol
DO  - 10.3389/fonc.2026.1856689
UR  - https://doi.org/10.3389/fonc.2026.1856689
ER  -

APA

T, J., C, G., F, D., S, C., & Q., C. (2026). Long-term follow-up of tislelizumab combined with anlotinib in a single patient with metastatic type B3 thymoma: a case report.. Front Oncol. https://doi.org/10.3389/fonc.2026.1856689

Source records

europe-pmc · retrieved 2026-09-27T02:44:39.081Z
doaj · retrieved 2026-09-27T02:44:39.086Z